CLSN - Celsion shares surge 51% following ovarian cancer candidate Fast Track designation

The FDA has granted Fast Track designation to Celsion's (CLSN) GEN-1, an immunotherapy in phase 2 for advanced ovarian cancer.The phase 2 study, known as OVATION 2, of the DNA-mediated interleukin-12 (IL-12) candidate is combining GEN-1 with standard-of-care neoadjuvant chemotherapy in newly diagnosed patients with stage 3/4 ovarian cancer.Results from the phase 1 portion of the study showed that 88% of patients in the GEN-1 arm had complete tumor resection compared to 50% in the standard-of-care chemotherapy group.Celsion shares are up 51% to $2.87 in premarket trading.

For further details see:

Celsion shares surge 51% following ovarian cancer candidate Fast Track designation